SPAC17A2.14 Antibody

What is the SPAC17A2.14 antibody and what cellular components does it target?

The SPAC17A2.14 antibody is a polyclonal antibody raised in rabbits against the SPAC17A2.14 protein from Schizosaccharomyces pombe (fission yeast, strain 972/24843). This antibody targets a putative metal ion transporter from the CorA family of magnesium ion transporters . The protein is also referred to by alternative names including "C17A12.14" and "SPAC17G6.01" in some databases. It specifically recognizes epitopes of this transmembrane protein involved in magnesium ion transport across cellular membranes.

What are the validated applications for SPAC17A2.14 antibody in yeast research?

The SPAC17A2.14 antibody has been validated for:

• ELISA (Enzyme-Linked Immunosorbent Assay) for quantitative detection

• Western Blot analysis for protein identification

When using this antibody for research applications, it's important to confirm proper identification of the antigen. Unlike antibodies against common mammalian targets like CD3 or cytokeratin, which have extensive validation data across multiple applications , specialized yeast protein antibodies may require additional optimization steps for each application.

How should I optimize Western blot protocols when using SPAC17A2.14 antibody?

Optimizing Western blot protocols for SPAC17A2.14 antibody requires:

• Sample preparation considerations:

  • Use specialized yeast lysis buffers containing protease inhibitors

  • Include detergents appropriate for membrane proteins (e.g., 1% Triton X-100)

  • Consider glass bead disruption methods for efficient yeast cell wall breakage

• Blotting parameters:

  • Transfer using standard PVDF membranes (0.45 μm pore size)

  • Block with 5% non-fat milk or BSA in TBST

  • Initial antibody dilution: 1:500-1:1000 (optimize as needed)

  • Secondary antibody: Anti-rabbit IgG HRP conjugate at 1:5000 dilution

• Detection optimization:

  • Extended exposure times may be required (2-15 minutes)

  • Consider enhanced chemiluminescence detection systems

  • Validate with appropriate positive controls from S. pombe lysates

Unlike widely-used antibodies that have standardized protocols , specialized yeast antibodies require empirical optimization for each laboratory setting.

How can I validate the specificity of SPAC17A2.14 antibody in knockout/mutant S. pombe strains?

Validating antibody specificity using genetic approaches is critical for less commonly used research antibodies. For SPAC17A2.14:

• Generate validation controls:

  • Use CRISPR-Cas9 or homologous recombination to create SPAC17A2.14 knockout strains

  • Alternatively, use temperature-sensitive mutants if the gene is essential

  • Create epitope-tagged versions (HA, FLAG, etc.) for parallel validation

• Perform comparative analyses:

  Sample Type	Expected Western Blot Result	ELISA Signal	Notes
  Wild-type S. pombe	Band at ~45 kDa	High signal	Positive control
  ΔSPAC17A2.14 strain	No specific band	Background only	Negative control
  Tagged SPAC17A2.14	Size-shifted band	High signal	Confirmatory control

• Cross-reactivity assessment:

  • Test against closely related CorA family transporters

  • Evaluate potential cross-reactivity with S. cerevisiae homologs

This validation approach mirrors knockout validation techniques used for commercial antibodies like those against cytokeratin 14, which employ KRT14 knockout cell lines .

What strategies can address non-specific binding issues with SPAC17A2.14 antibody in immunoprecipitation experiments?

Non-specific binding is a common challenge with polyclonal antibodies against lesser-studied proteins. For SPAC17A2.14 antibody:

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads (30-60 minutes at 4°C)

  • Add non-immune rabbit IgG during pre-clearing

  • Filter lysates through 0.45 μm filters before immunoprecipitation

• Blocking optimization:

  • Test alternative blocking agents (BSA, fish gelatin, commercial blockers)

  • Include 0.1-0.5% detergents (NP-40 or Triton X-100) in wash buffers

  • Consider adding competing peptides that don't contain the target epitope

• Elution considerations:

  • Use acid elution (0.1M glycine, pH 2.5) rather than denaturing conditions

  • Neutralize immediately with Tris buffer (pH 8.0)

  • Validate specificity with mass spectrometry analysis of eluates

This approach builds on established immunoprecipitation methodologies used for well-characterized antibodies in research settings .

How should I design experiments to investigate the localization of SPAC17A2.14 protein using immunofluorescence?

For immunofluorescence studies of SPAC17A2.14:

• Cell preparation:

  • Fix with 4% paraformaldehyde (10-15 minutes)

  • Permeabilize with enzyme cocktails optimized for yeast cell walls

  • Consider spheroplast preparation for improved antibody accessibility

• Staining protocol optimization:

  • Extended primary antibody incubation (overnight at 4°C)

  • Higher primary antibody concentration (1:50-1:200)

  • Use high-sensitivity detection systems (tyramide signal amplification)

• Controls and co-localization:

  • Include DAPI nuclear staining

  • Use markers for cellular compartments (ER, Golgi, plasma membrane)

  • Compare with GFP-tagged SPAC17A2.14 expression patterns

• Microscopy considerations:

  • Use confocal microscopy with appropriate filter sets

  • Acquire Z-stacks to capture full cellular distribution

  • Apply deconvolution algorithms to improve signal-to-noise ratio

Unlike antibodies against structural proteins like cytokeratin 14 , membrane transporters may require specialized immunofluorescence approaches.

How do I quantitatively assess SPAC17A2.14 protein expression levels across different growth conditions?

For quantitative assessment of SPAC17A2.14 expression:

• Experimental design:

  • Test multiple growth media (minimal, rich, defined)

  • Examine various metal ion stress conditions (Mg²⁺ depletion/excess)

  • Sample at different growth phases (log, early stationary, late stationary)

• Quantification methods:

  Method	Advantages	Limitations	Controls Needed
  Western blot + densitometry	Semi-quantitative, visual verification	Limited dynamic range	Loading control (e.g., GAPDH)
  ELISA	Higher throughput, better quantitation	No size verification	Standard curve with recombinant protein
  Flow cytometry	Single-cell resolution	Requires cell permeabilization	Isotype control antibody

• Data normalization:

  • Normalize to total protein content (BCA/Bradford assay)

  • Use housekeeping gene products as internal controls

  • Consider spike-in standards for absolute quantification

This approach is similar to expression analysis methods used for other cellular proteins, though with specific considerations for membrane transporters .

What are the key considerations when using SPAC17A2.14 antibody in co-immunoprecipitation to identify protein interaction partners?

For co-immunoprecipitation with SPAC17A2.14 antibody:

• Sample preparation:

  • Use mild lysis conditions to preserve protein-protein interactions

  • Include stabilizing agents (10% glycerol, divalent cations)

  • Avoid harsh detergents (use digitonin or CHAPS instead of SDS)

• Experimental controls:

  • Input control (pre-IP lysate)

  • IgG control (non-immune rabbit IgG)

  • Bead-only control (no antibody)

  • Reciprocal IP with antibodies against suspected interactors

• Validation of interactions:

  • Direct western blot for known/suspected partners

  • Mass spectrometry for unbiased discovery

  • Confirmation with alternative methods (Y2H, FRET, PLA)

• Specific challenges for membrane transporters:

  • Consider crosslinking before lysis (1-2% formaldehyde, 10 minutes)

  • Test detergent panel for optimal solubilization

  • Evaluate buffer ionic strength effects on interaction stability

This methodology adapts standard co-IP procedures used for other proteins while addressing specific challenges of membrane protein complexes .

How can I troubleshoot weak or inconsistent signals when using SPAC17A2.14 antibody?

When facing weak or inconsistent signals:

• Sample-related factors:

  • Increase protein loading (50-100 μg total protein)

  • Verify protein extraction efficiency from yeast cells

  • Check for proteolytic degradation (add additional protease inhibitors)

• Antibody-related factors:

  • Test new antibody dilutions (1:100-1:1000 range)

  • Extend primary antibody incubation (overnight at 4°C)

  • Try alternative detection systems (enhanced chemiluminescence)

• Protocol modifications:

  • Extend blocking time (2-3 hours)

  • Add 0.1% SDS to antibody dilution buffer

  • Increase washing stringency (higher salt concentration)

• Storage and handling:

  • Avoid repeated freeze-thaw cycles of antibody

  • Prepare fresh working dilutions for each experiment

  • Add antibody stabilizers (1% BSA, 0.02% sodium azide)

Unlike heavily studied antibodies against proteins like CD3 or Snail1 , specialized antibodies may require more extensive troubleshooting.

How does the performance of polyclonal SPAC17A2.14 antibody compare with monoclonal alternatives for research applications?

While the currently available SPAC17A2.14 antibody is polyclonal , it's useful to understand comparative performance characteristics:

What controls should be included when evaluating SPAC17A2.14 antibody performance in newly developed assays?

For robust assay development:

• Positive controls:

  • Wild-type S. pombe extracts

  • Recombinant SPAC17A2.14 protein (if available)

  • Cells with overexpressed SPAC17A2.14

• Negative controls:

  • SPAC17A2.14 knockout strains

  • Pre-immune serum

  • Primary antibody omission

  • Competing peptide blocking

• Specificity controls:

  • Related protein family members

  • Cross-species testing (if relevant)

  • Tag-only controls for fusion proteins

• Quantitative controls:

  • Standard curves with known protein amounts

  • Dilution series to establish linear detection range

  • Spike-in controls for sample matrix effects

This control strategy aligns with best practices established for antibody validation in research applications, similar to approaches used for other research antibodies .

How can advanced proteomics approaches be combined with SPAC17A2.14 antibody for comprehensive transport protein research?

Integrating proteomics with SPAC17A2.14 antibody research:

• Immunoprecipitation-mass spectrometry (IP-MS):

  • Use the antibody to enrich SPAC17A2.14 and associated proteins

  • Apply label-free quantitation to determine relative abundance

  • Perform SILAC labeling for comparative studies across conditions

• Proximity labeling approaches:

  • Express SPAC17A2.14 fused to BioID or APEX2

  • Identify proximal proteins through streptavidin pulldown

  • Validate key interactions using SPAC17A2.14 antibody

• Antibody-based proteomic profiling:

  • Perform reverse-phase protein arrays using the antibody

  • Develop multiplex assays with other transporter antibodies

  • Create quantitative assays for post-translational modifications

• Data integration:

  • Correlate antibody-based detection with transcriptomic data

  • Map interaction networks through multiple methods

  • Validate findings from high-throughput methods with targeted approaches

This integration of techniques represents an advanced research approach similar to those employed for other proteins in complex research scenarios .

How can SPAC17A2.14 antibody be used to investigate the role of this transporter in metal ion homeostasis?

For metal ion homeostasis studies:

• Expression correlation studies:

  • Monitor SPAC17A2.14 protein levels under various metal stresses

  • Compare expression across magnesium-limiting and excess conditions

  • Correlate with cellular metal content measured by ICP-MS

• Subcellular localization changes:

  • Track redistribution under different ionic conditions

  • Co-localize with other transporters and metal sensors

  • Examine expression in metal-sensitive yeast mutants

• Functional correlation:

  • Correlate protein levels with transport activity measurements

  • Examine post-translational modifications under stress conditions

  • Investigate protein stability and turnover using cycloheximide chase

• Comparative studies:

  Condition	Expected SPAC17A2.14 Expression	Cellular Localization	Functional Impact
  Mg²⁺ depletion	Upregulation	Enhanced plasma membrane	Increased transport activity
  Mg²⁺ excess	Potential downregulation	Partial internalization	Reduced transport activity
  Other metal stress	Context-dependent	Possible redistribution	Compensatory regulation

This research direction adapts approaches used in studying other transport proteins and their regulation in cellular systems.

What experimental approaches can determine if post-translational modifications affect SPAC17A2.14 function?

For investigating post-translational modifications (PTMs):

• PTM detection strategies:

  • Phosphorylation-specific detection using phospho-antibodies after IP

  • Mobility shift assays (Phos-tag gels) with SPAC17A2.14 antibody

  • Lambda phosphatase treatment to confirm phosphorylation

  • Mass spectrometry analysis of immunoprecipitated protein

• Functional correlation:

  • Site-directed mutagenesis of potential PTM sites

  • Correlation of modification status with transport activity

  • Temporal analysis during stress responses

  • Manipulation of relevant kinases/phosphatases

• Regulation mechanisms:

  • Examine PTM changes during cell cycle progression

  • Assess impact of osmotic/oxidative stress on modification status

  • Investigate crosstalk between different modification types

This methodological approach is similar to studies of post-translational regulation of other transport proteins and signaling molecules .

How can the SPAC17A2.14 antibody be used in comparative studies across different yeast species?

For cross-species comparative studies:

• Homology assessment:

  • Alignment of SPAC17A2.14 with homologs from other yeasts

  • Epitope conservation analysis across species

  • Western blot testing against multiple species extracts

• Functional conservation studies:

  • Compare expression patterns in response to metal stress

  • Assess subcellular localization across species

  • Evaluate heterologous complementation in knockout strains

• Evolutionary insights:

  • Correlate antibody reactivity with evolutionary distance

  • Examine conservation of regulatory mechanisms

  • Investigate species-specific interaction partners

• Technical considerations:

  • Optimize extraction conditions for each species

  • Adjust antibody concentrations for cross-reactivity differences

  • Include appropriate controls for each species

This approach leverages techniques from evolutionary proteomics while addressing specific challenges of transport protein research across species .